Pyridoxine supplementation for levetiracetam-related neuropsychiatric adverse events in pediatric and adolescent epilepsy: a prospective, double-blind, randomized, placebo-controlled trial.

Background: Levetiracetam commonly causes neuropsychiatric adverse events (NPAEs) in pediatric patients, including irritability and aggression. This study evaluated pyridoxine supplementation for reducing levetiracetam-related NPAEs in children and adolescents with epilepsy.

Methods: We conducted a prospective, double-blind, randomized, placebo-controlled trial at Phramongkutklao Hospital, Thailand (January-June 2024).